Ocugen Stock Analysis


USD 1.82  0.07  4.00%   

Ocugen Inc price slide over the last few months may encourage institutional investors to take a closer look at the company as it is trading at a share price of 1.82 on 5,241,974 in trading volume. The company executives were not very successful in positioning the company resources to exploit market volatility in August. However, diversifying your holdings with Ocugen Inc or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.46. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Ocugen partners.
Please check Your Equity Center.
The Ocugen stock analysis report makes it easy to digest most publicly released information about Ocugen and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ocugen Stock analysis module also helps to analyze the Ocugen price relationship with some important fundamental indicators such as market cap and management efficiency.

Ocugen Stock Analysis Notes

About 40.0% of the company shares are owned by institutional investors. The book value of Ocugen was now reported as 0.54. The company recorded a loss per share of 0.25. Ocugen Inc had not issued any dividends in recent years. The entity had a split on the 30th of September 2019. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing and Bharat Biotech for the commercialization of COVAXIN in the United States market. Ocugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To find out more about Ocugen Inc contact the company at 484 328 4701 or learn more at https://www.ocugen.com.

Ocugen Inc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ocugen's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ocugen Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ocugen Inc generated a negative expected return over the last 90 days
Ocugen Inc has high historical volatility and very poor performance
Ocugen Inc may become a speculative penny stock
Net Loss for the year was (69.31 M) with loss before overhead, payroll, taxes, and interest of (35.11 M).
Ocugen Inc currently holds about 129.77 M in cash with (57.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Latest headline from seekingalpha.com: OCGN stock on watch after peer-reviewed publication on COVID-19 vaccine - Seeking Alpha

Ocugen Inc Upcoming and Recent Events

Earnings reports are used by Ocugen to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ocugen previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report26th of March 2021
Next Financial Report14th of May 2021
Next Fiscal Quarter End31st of December 2020
Next Fiscal Year End26th of March 2021
Last Quarter Report30th of September 2020
Last Financial Announcement31st of December 2019

Ocugen Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Ocugen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ocugen Inc backward and forwards among themselves. Ocugen's institutional investor refers to the entity that pools money to purchase Ocugen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
State Street CorpCommon Shares30.6 M69.5 M
Blackrock IncCommon Shares13.8 M31.3 M
Vanguard Group IncCommon Shares11.4 M25.9 M
Geode Capital Management LlcCommon Shares3.7 M8.4 M
Jpmorgan Chase CoCommon Shares3.3 M7.5 M
Morgan StanleyCommon Shares2.5 M5.7 M
Northern Trust CorpCommon SharesM4.6 M
Susquehanna International Group LlpPut Options541.2 K1.2 M
Note, although Ocugen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Ocugen Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 348.58 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ocugen's market, we take the total number of its shares issued and multiply it by Ocugen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (44.1) % which means that it has lost $44.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (78.04) %, meaning that it created substantial loss on money invested by shareholders. Ocugen management efficiency ratios could be used to measure how well ocugen inc manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Ocugen holds the coefficient of variation of (1,281), and Risk Adjusted Performance of (0.08). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ocugen, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Ocugen Inc, which can be compared to its competitors. Please check Ocugen Inc jensen alpha and downside variance to decide if Ocugen Inc is priced some-what accurately, providing market reflects its current price of 1.82 per share. Please also confirm Ocugen Inc total risk alpha, which is currently at (0.08) to check out the company can sustain itself at a future point.

Ocugen Inc Price Movement Analysis

The output start index for this execution was thirty-four with a total number of output elements of twenty-seven. The Weighted Moving Average calculates a weight for each value in Ocugen price series with the more recent values given greater weights.

Ocugen Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocugen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocugen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ocugen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Castillo Kirsten over a month ago via Macroaxis 
Exercise or conversion by Castillo Kirsten of 42000 shares of Ocugen subject to Rule 16b-3
Musunuri Shankar over two months ago via Macroaxis 
Exercise or conversion by Musunuri Shankar of 150000 shares of Ocugen subject to Rule 16b-3
Castillo Kirsten over three months ago via Macroaxis 
Acquisition by Castillo Kirsten of 140091 shares of Ocugen subject to Rule 16b-3
Musunuri Shankar over three months ago via Macroaxis 
Exercise or conversion by Musunuri Shankar of 125000 shares of Ocugen subject to Rule 16b-3
Kumar Ramesh over three months ago via Macroaxis 
Exercise or conversion by Kumar Ramesh of 7500 shares of Ocugen subject to Rule 16b-3
Crespo Jessica over six months ago via Macroaxis 
Ocugen exotic insider transaction detected
Crespo Jessica over six months ago via Macroaxis 
Acquisition by Crespo Jessica of 84192 shares of Ocugen subject to Rule 16b-3
Musunuri Shankar over six months ago via Macroaxis 
Exercise or conversion by Musunuri Shankar of 81823 shares of Ocugen subject to Rule 16b-3
Zhang Junge over six months ago via Macroaxis 
Exercise or conversion by Zhang Junge of 000 shares of Ocugen subject to Rule 16b-3
Musunuri Shankar over six months ago via Macroaxis 
Exercise or conversion by Musunuri Shankar of 90000 shares of Ocugen subject to Rule 16b-3
Musunuri Shankar over six months ago via Macroaxis 
Exercise or conversion by Musunuri Shankar of 90000 shares of Ocugen subject to Rule 16b-3
Kompella Uday over six months ago via Macroaxis 
Acquisition by Kompella Uday of 16335 shares of Ocugen subject to Rule 16b-3

Ocugen Predictive Daily Indicators

Ocugen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ocugen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Ocugen Forecast Models

Ocugen time-series forecasting models is one of many Ocugen's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ocugen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ocugen Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ocugen prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ocugen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Ocugen. By using and applying Ocugen Stock analysis, traders can create a robust methodology for identifying Ocugen entry and exit points for their positions.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing and Bharat Biotech for the commercialization of COVAXIN in the United States market. Ocugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.

Current Ocugen Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ocugen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ocugen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Ocugen Inc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ocugen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ocugen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ocugen Inc, talking to its executives and customers, or listening to Ocugen conference calls.
Ocugen Analyst Advice Details

Ocugen Stock Analysis Indicators

Ocugen Inc stock analysis indicators help investors evaluate how Ocugen stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ocugen shares will generate the highest return on investment. By understating and applying Ocugen stock analysis, traders can identify Ocugen position entry and exit signals to maximize returns.
Quick Ratio16.88
Fifty Two Week Low1.6700
Shares Short Prior Month54.69M
Average Daily Volume Last 10 Day5.68M
Average Daily Volume In Three Month5.23M
Shares Percent Shares Out25.01%
Short Percent Of Float34.16%
Forward Price Earnings-5.30
Float Shares211.54M
Fifty Two Week High17.6500
Enterprise Value To Ebitda-6.25
Fifty Day Average2.5136
Two Hundred Day Average3.0190
Please check Your Equity Center. Note that the Ocugen Inc information on this page should be used as a complementary analysis to other Ocugen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Ocugen Stock analysis

When running Ocugen Inc price analysis, check to measure Ocugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocugen is operating at the current time. Most of Ocugen's value examination focuses on studying past and present price action to predict the probability of Ocugen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ocugen's price. Additionally, you may evaluate how the addition of Ocugen to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Transaction History
View history of all your transactions and understand their impact on performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Ocugen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine Ocugen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.